1. Martin JP Herberg JT Slatter JG Dupuis MJ Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive (reversible) inhibitor of human monoamine oxidase (MAO A), no clinical evidence of MAO A inhibition in clinical trials has been observed September 1998
2. Pawsey SD Daley-Yates PT Wajszczuk CP Stalker DJ U-100766 Safety, toleration and pharmacokinetics after oral and intravenous administration [abstract F151] May 1996
3. Feenstra KL Slatter JG Stalker DJ Welshman IR Hauer MJ Cathcart KS et al Metabolism and excretion of the oxazolidinone antibiotic linezolid (PNU-100766) following oral administration of [ 14 C]PNU-100766 to healthy volunteers September 1998
4. Stalker DJ Wajszczuk CP Batts DH Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days September 1997
5. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam;Sisson;J Clin Pharmacol,1999